Biomarkers for disease areas
Roche Diagnostics evaluates new biomarker opportunities by continuously monitoring universities, start-ups, medical and research institutes, mid sized and large companies.
The goal is to identify biomarkers that address significant unmet medical needs to enable novel and important physician decision making along the entire continuum of a patient’s journey.
Roche’s tests provide crucial knowledge about the different diseases during the whole spectrum of care (screening - diagnosis - prognosis - prediction - monitoring), enabling physicians and caretakers to intervene early and to actively manage patients’ health conditions.
We are interested in clinically validated biomarkers in a variety of indications including:
- Cardiovascular diseases
- Infectious diseases
- Central nervous system diseases, including brain traumatism
- Women's health
- Respiratory diseases
- Coagulation and haematology
- Autoimmune diseases and inflammation
- Diabetes and other metabolic diseases
The biomarker-driven drug development across the industry is driving the group's personalised healthcare strategy across many therapeutic areas for different intended uses.